Luxurynsight and Heuritech, two French AI & Data Leaders unite to unlock next-level data intelligence for Luxury, Fashion and Beauty Brands
PARIS, Dec. 2, 2024 /PRNewswire/ -- As from November 2024, Heuritech has officially…
Luxurynsight and Heuritech, two French AI & Data Leaders unite to unlock next-level data intelligence for Luxury, Fashion and Beauty Brands
PARIS, Dec. 2, 2024 /PRNewswire/ -- As from November 2024, Heuritech has officially…
Schneider Electric advances environmental impact transparency in MEP by sharing product data through One Click LCA
First-of-its-kind environmental initiative addresses the critical data shortage for MEP products needed to…
Menarini Group Presents New and Expanded Data at the 2024 San Antonio Breast Cancer Symposium Reinforcing the Role of ORSERDU (Elacestrant) for Patients with ER+, HER2- Advanced or Metastatic Breast Cancer (mBC)
Real-world evidence bolsters the efficacy of ORSERDU for the treatment of patients…
Menarini Group Presents New and Expanded Data at the 2024 San Antonio Breast Cancer Symposium Reinforcing the Role of ORSERDU (Elacestrant) for Patients with ER+, HER2- Advanced or Metastatic Breast Cancer (mBC)
Real-world evidence bolsters the efficacy of ORSERDU for the treatment of patients…
Menarini Group Presents New and Expanded Data at the 2024 San Antonio Breast Cancer Symposium Reinforcing the Role of ORSERDU (Elacestrant) for Patients with ER+, HER2- Advanced or Metastatic Breast Cancer (mBC)
Real-world evidence bolsters the efficacy of ORSERDU for the treatment of patients…
Atomic Data Becomes Official IT Provider of the Fishers Event Center
MINNEAPOLIS, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Atomic Data today announced a…
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH
-- Achieved all co-primary endpoints of LS mean reduction in LDL-C on…
Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months
November 18, 2024 11:15 ET | Source: BridgeBio Pharma, Inc. - Acoramidis…
Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024
SAN FRANCISCO, Nov. 17, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq:…